The US Food and Drug Administration’s conundrum about unlawful but widespread sales of cannabidiols in dietary supplements has continued so long that industry stakeholders may forget agency executives have said Congress could solve the problem more efficiently.
The FDA soon could get what it requested, says the United Natural Products Alliance.








